Pharmigene (ROCO:7595) Cash Flow for Dividends: NT$0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7595 Pharmigene Inc ROCO:7595
54 GF Score
Price NT$6.30
GF Value NT$24.76
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Pharmigene Cash Flow for Dividends?

Pharmigene ROCO:7595 -2.33% 54 Cash Flow for Dividends is NT$0.0 Mil as of Dec. 2025. GuruFocus rates ROCO:7595 with a GF Score™ of 54/100 and a GF Value™ of NT$24.76 (Possible Value Trap). The stock has 7 warning signs investors should review.

Pharmigene's cash flow for dividends for the six months ended in Dec. 2025 was NT$0.0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Pharmigene Cash Flow for Dividends Related Terms

Pharmigene Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Pharmigene's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmigene Cash Flow for Dividends Chart

Pharmigene Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pharmigene Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:7595
54GF Score
Pharmigene Inc ROCO:7595
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmigene Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of NT$0.0 Mil mean?
Pharmigene (ROCO:7595) has a Cash Flow for Dividends of NT$0.0 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Pharmigene and its competitors.
Is Pharmigene's Cash Flow for Dividends too high?
Pharmigene's current Cash Flow for Dividends is NT$0.0 Mil. Overall, Pharmigene has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharmigene's Cash Flow for Dividends compare to TMO and DHR?
Pharmigene's Cash Flow for Dividends of NT$0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Medical Diagnostics & Research company?
A good Cash Flow for Dividends depends on the Medical Diagnostics & Research industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Pharmigene and its competitors. Pharmigene's current Cash Flow for Dividends is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmigene stock overvalued right now?
Based on GuruFocus' analysis, Pharmigene (ROCO:7595) is currently considered Possible Value Trap. The stock's GF Value™ is NT$24.76, compared to a current price of NT$6.30 — trading 74.6% below its estimated fair value. The current Cash Flow for Dividends is NT$0.0 Mil. Pharmigene's overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Pharmigene (ROCO:7595), the current Cash Flow for Dividends is NT$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmigene (ROCO:7595) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmigene stock appears to be undervalued. The current stock price of NT$6.30 is trading 74.6% below its estimated GF Value™ of NT$24.76. GuruFocus considers Pharmigene to be Possible Value Trap.

Key valuation signals for ROCO:7595:

  • Cash Flow for Dividends: NT$0.0 Mil
  • GF Value™: NT$24.76 vs. price of NT$6.30 (74.6% below fair value)
  • GF Score™: 54/100 with 7 warning signs

No single metric tells the full story. See the ROCO:7595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmigene Business Description

Address No. 17, Lane 171, Section 2, Jiuzong Road, 4th Floor, Neihu District, Taipei, TWN, 11494
Pharmigene Inc is engaged in the development and sales of pharmaceutical genetic diagnostic products. Also, the company provides medical and drug testing services and equipment.
54GF Score

Get the complete analysis for ROCO:7595

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$6.30
Price
NT$24.76
GF Value